Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue 1
Submit an article Journal homepage
239
Views
13
CrossRef citations to date
0
Altmetric
Infection

Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies

Aditya K. GuptaDepartment of Medicine, University of Toronto, Toronto, Canada; ;Mediprobe Research Inc., London, Canada; Correspondence[email protected]
View further author information
,
Steve HallMedical Affairs, Sandoz Pharmaceuticals Inc., Princeton, NJ, USA; View further author information
,
Lee T. ZaneAnacor Pharmaceuticals Inc., Palo Alto, CA, USA; View further author information
,
Shari R. LipnerDepartment of Dermatology, Weill Cornell Medicine, New York, NY, USA; View further author information
&
Phoebe RichOregon Dermatology and Research, Portland, OR, USAView further author information
Pages 44-48 | Received 13 Mar 2017, Accepted 17 Mar 2017, Published online: 30 May 2017

References

  • Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.
  • Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol. 1997;133:1172–3.
  • Vender RB, Lynde CW, Poulin Y. Prevalence and epidemiology of onychomycosis. J Cutan Med Surg. 2006;10:S28–S33.
  • Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748–52.
  • Scher RK. Advances in the diagnosis and treatment of onychomycosis. Hosp Med. 1998;34:11–20.
  • Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35:497–519.
  • Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38:702–4.
  • Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol. 1994;130:15.
  • Niewerth M, Korting HC. Management of onychomycoses. Drugs. 1999;58:283–96.
  • Nenoff P, Kruger C, Ginter-Hanselmayer G, Tietz HJ. Mycology – an update. Part 1: dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014;12:188–209.
  • Arrese JE, Pierard-Franchimont C, Pierard GE. A plea to bridge the gap between antifungals and the management of onychomycosis. Am J Clin Dermatol. 2001;2:281–4.
  • Arrese JE, Pierard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (Basel). 2003;207:255–60.
  • Sporanox (Itraconazole) Capsules [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc., 2014.
  • Lamisil (Terbinafine Hydrochloride) Tablets, 250 mg for Oral Use [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2015.
  • Penlac Nail Lacquer (Ciclopirox) Topical Solution, 8% [package insert]. Bridgewater (NJ): Dermik Laboratories, 2006.
  • Jublia (Efinaconazole) Topical Solution, 10% [package insert]. Shizuoka: Kaken Pharmaceutical Co Ltd, 2015.
  • Kerydin (Tavaborole) Topical Solution, 5% [package insert]. Palo Alto, CA: Anacor Pharmaceuticals Inc., 2015.
  • Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.
  • Hold KM, Sanders V, Bu W, et al. Nail penetration and nail concentration of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Poster presented at: Annual Meeting of the American Association of Pharmaceutical Scientists; October 29–November 2, 2006; San Antonio, TX.
  • Elewski BE, Tosti A. Tavaborole for the treatment of onychomycosis. Expert Opin Pharmacother. 2014;15:1439–48.
  • De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol. 1999;141:15–20.
  • Werschler WP, Bondar G, Armstrong D. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol. 2004;5:145–52.
  • Gupta AK, Lynch LE. Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis. 2004;74:10–15.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.